Skip to main content

Axel Hoos, The Keeper Of The Oncology Flame At Glaxosmithkline, Steps Away For His Next Challenge At Tiny Scorpion

Axel Hoos has long kept the flame alive at GlaxoSmithKline’s oncology division, enduring lean days after the British pharma ditched its late-stage pipeline to Novartis and decided to rebuild anew. Now, watching the pipeline he helped remold finally bear fruit, Hoos is ready for a new challenge — and it will come at a tiny biotech at the frontier of “precision medicine 2.0.”

Read more